TB-500 side effects: the questions without a leaflet

Is TB-500 safe, and what are its side effects?

The fragment has no characterized human side-effect profile. There is no completed controlled clinical trial of the TB-500 heptapeptide for any indication, and no long-term human safety dataset for it. The Phase 1 intravenous study in 40 healthy volunteers used full-length thymosin beta-4, reported infrequent mild or moderate events, and found no serious adverse events.

The fragment still has no side-effect profile

I cannot make that reassuring protein result answer a different molecule's safety question. Community reports of local reactions, tiredness, headaches, nausea or mood changes are anecdotal accounts, not clinical evidence. They supply neither a reliable side-effect rate nor proof that the fragment caused them.

Does TB-500 cause cancer?

The cited studies do not demonstrate that TB-500 causes cancer in people. They do supply a biologically specific concern. In tumour models and cell lines, thymosin beta-4 was implicated in metastasis and angiogenesis—the formation of new blood vessels. Work in human pancreatic cancer cells in culture found the parent protein overexpressed and linked it to cytokine secretion and JNK activation. Those findings describe the laboratory models; a human fragment-risk estimate remains unavailable.

The cancer concern deserves my attention precisely because cell movement and blood-vessel growth can serve a tumour as well as a repairing tissue. It remains a theoretical oncologic concern for TB-500; neither declaring the fragment carcinogenic nor dismissing the signal as harmless is supported here.

Is TB-500 a steroid?

No. The TB-500 identified in the analytical literature is the Ac-LKKTETQ peptide fragment from thymosin beta-4, not a steroid hormone. Its actin-related rationale differs from androgen-receptor signalling. That chemical distinction says what it is; it does not confer safety or remove its WADA prohibition.

What changes with BPC-157 beside it?

TB-500 and BPC-157 are different peptides with different origins and proposed mechanisms. BPC-157 is gastric-derived; TB-500 reproduces an actin-binding stretch of thymosin beta-4. The sports-medicine review discusses both among unapproved peptides with favourable animal repair findings and scarce human safety data.

A combined human protocol has not been validated in controlled trials. The combination needs evidence of its own; that is the claim I would need tested.

What about surgery, clotting, pregnancy or breastfeeding?

The cautions about bleeding, surgery and clotting are theoretical: this record contains no direct human fragment study measuring those risks. The concern arises from the parent protein's involvement in cell movement, new-vessel formation and its release by platelets at injury sites, described in the thymosin beta-4 review.

Pregnancy, breastfeeding and developmental safety are also unstudied for TB-500 in people. Because those cellular processes are basic to development, the caution rests on the mechanism; harm or safety in these populations remains unmeasured. Reassurance about an unstudied population is a claim I cannot justify.

Does prescription access mean FDA approval?

No. TB-500 has no FDA-approved human therapeutic indication. On FDA's page current as of April 22, 2026, its nomination is recorded as withdrawn and it is no longer in 503A Category 2. FDA does not explain there what the withdrawal permits a compounding pharmacy to do. A prescription and approval of a finished drug are different questions; the legal-status page carries the full distinction.